By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors 9/29/2015 6:36:03 AM
DelMar Pharmaceuticals To Present An Interactive Live Webcast At On October 1, 2015 9/28/2015 12:29:35 PM
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme At GBM2015 9/10/2015 6:06:45 AM
DelMar Pharmaceuticals Presents Clinical Protocol For Advancement Of VAL-083 Into Phase IV Studies As A Treatment For Non-Small Cell Lung Cancer 9/8/2015 9:46:27 AM
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results And Provides Corporate Update 9/4/2015 6:35:32 AM
DelMar Pharmaceuticals Announces Expansion Of VAL-083 Development Program To Include Ovarian Cancer 9/2/2015 6:57:37 AM
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015 6:36:29 AM
DelMar Pharmaceuticals To Present At The 17th Annual Rodman & Renshaw Global Investment Conference On September 9, 2015 8/25/2015 8:08:38 AM
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015 6:30:26 AM
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015 6:35:04 AM